Pharmaceutical Industry Veteran Dr. Kurt R. Nielsen to lead Pharmaceutics International, Inc. (Pii)
HUNT VALLEY, Md. /PRNewswire/ --Pharmaceutics International, Inc. (Pii), a Contract Development and Manufacturing Organization (CDMO) headquartered in Hunt Valley, Maryland, is pleased to announce the appointment of Kurt R. Nielsen, Ph.D., to the position of President and CEO, effective immediately. Dr. Nielsen is a seasoned pharmaceutical executive with over 20 years of diverse experience, most recently as the President of Lupin Somerset, responsible for all their generic and branded products. Prior to Lupin, he held the post of Vice President, U.S. Development, Portfolio and Launch Management at Sandoz Inc., where he was accountable for the U.S. development of generic, OTC and specialty brand products. Dr. Nielsen has also held positions at Catalent, where he was Senior Vice President of R&D and Chief Technology Officer, and URL Pharma where he was the Executive Vice President, Pharmaceuticals. With the appointment of Dr. Nielsen to President and CEO, Pii further announces that Dr. Abidi, Founder and former CEO of Pii, will transition into an advisory role and as the Executive Chairman.
Dr. Nielsen commented, "As we enter the 25th year of service to our valued partners, Pii is well-positioned to outpace the growth of the CDMO market with our depth and breadth of expertise in development and reliable supply of Branded, Specialty Generic and OTC products."
"The appointment of Dr. Nielsen to the position of President and CEO reflects a further commitment to growth, building upon Pii's legacy of success, his diverse experiences, proven leadership and industry insights will be instrumental in achieving our strategic objectives," said Dr. Abidi, Pii's Founder and Executive Chairman of the Board of Directors.
About Pharmaceutics International, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/pharmaceutical-industry-veteran-dr-kurt-r-nielsen-to-lead-pharmaceutics-international-inc-pii-300778571.html
SOURCE Pharmaceutics International, Inc.